YiChang HEC ChangJiang Pharmaceutical financials at a glance

+ Portfolio

The revenue of YiChang HEC ChangJiang Pharmaceutical is reported as 6.15385 billion Dollars in the fiscal year 2023. The earnings were 1.74 Dollars per share in 2023, which was 259.7 higher than 2021. And about 2.036 billion Dollars are reported as free cash flow in the financials of YiChang HEC ChangJiang Pharmaceutical 2023. No dividends were paid to the shareholders of the YiChang HEC ChangJiang Pharmaceutical stock SEHK:1558 in the financial year 2023.

HK$3.74B

Revenue

HK$1.07

Earnings Per Share

76.00%

Gross Margin %

HK$0.00M

Free Cash Flow

Revenue

3,744.95

Earnings Per Share

1.07

Gross Margin %

76.00

Free Cash Flow

0.00

Financials

Year	Year	TTM	2022	2021	2020	2019	2018	2017	2016	2015
Rev.	Revenue	N/A	HK$3.74B	HK$913.79M	HK$2.35B	HK$6.22B	HK$2.51B	HK$1.60B	HK$941.50M	HK$692.91M
GM %	Gross Margin %	78.60%	76.00%	52.93%	85.03%	85.19%	84.11%	82.49%	77.25%	74.26%
OM	Operating Margin	27.63%	8.62%	-50.13%	45.19%	40.64%	43.16%	47.61%	44.56%	47.54%
EPS	Earnings Per Share	HK$1.29	HK$1.07	HK$-0.67	HK$0.53	HK$2.01	HK$1.05	HK$0.72	HK$0.42	HK$0.40
Div.	Dividends	N/A	HK$0.04	HK$0.00	HK$0.10	HK$0.65	HK$0.50	HK$0.35	HK$0.15	HK$0.08
PR %	Payout Ratio %	0	3.74%	-0.00%	18.87%	32.34%	47.62%	48.61%	35.71%	20.00%
Sha.	Shares	N/AM	879.97M	879.97M	879.97M	889.79M	904.05M	904.05M	901.65M	901.32M
OCF	Operating Cash Flow	N/A	HK$694.00M	HK$-,662.51M	HK$1.30B	HK$1.79B	HK$715.39M	HK$670.75M	HK$397.21M	HK$287.39M
FCF	Free Cash Flow	N/A	HK$123.93M	HK$-1,018.80M	HK$305.33M	HK$1.22B	HK$95.35M	HK$343.71M	HK$334.22M	HK$259.39M
FCFS	Free Cash Flow Per Share	HK$2.42	HK$0.96	HK$-1.41	HK$-0.70	HK$0.14	HK$-0.42	HK$0.33	HK$0.25	HK$-0.05

YiChang HEC ChangJiang Pharmaceutical financials at a glance

Financials

Discover